News Releases

November 6, 2018
Synlogic Presents Preclinical Data from First Synthetic BioticTM Clinical Candidate in Immuno-Oncology at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
– Data highlight the differential advantages of Synthetic Biotic approach designed to activate the local innate immune system for the potential treatment of a variety of solid tumors – – Company will webcast Investor and Analyst event at 12:30 pm ET , Saturday, November 10, 2018 , to discuss...
November 1, 2018
Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
- Presentations to feature key opinion leaders and expand on preclinical data from Synlogic’s first immuno-oncology candidate, accepted for presentation at SITC 2018 - - Company to webcast event, beginning at 12:30 p.m. ET on Saturday, November 10, 2018 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov....
October 2, 2018
Synlogic Appoints Dr. Aoife Brennan as President and Chief Executive Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the appointment of Aoife Brennan , M.B., B.Ch., as president and chief executive officer of...
September 25, 2018
Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 25, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare...
September 4, 2018
Synlogic Reports Positive Interim Phase 1/2a Data Demonstrating Safety, Tolerability and Proof-of-Mechanism in Healthy Volunteers for SYNB1618, in Development for the Management of Phenylketonuria (PKU)

– Data demonstrate statistically significant dose-dependent effects on SYNB1618 activity-associated biomarkers, supporting further development of SYNB1618 – – SYNB1618 dose established for treatment arm of ongoing Phase 1/2a study in patients with PKU; top-line data expected in mid-2019 – – Company

...
August 29, 2018
Synlogic to Webcast Presentation at the H. C. Wainwright 20th Annual Global Investment Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 29, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the H. C.

...
August 13, 2018
Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria
– Preclinical studies published in Nature Biotechnology identify key biomarkers of SYNB1618 activity in healthy animals and disease models – – Clinical data expected in 2018 from healthy volunteer cohorts of ongoing Phase 1/ 2a study of SYNB1618; data from patients with phenylketonuria (PKU) in...
August 8, 2018
Synlogic Reports Second Quarter 2018 Financial Results and Provides Program Updates
- Data from Phase 1/2 studies of SYNB1618 and SYNB1020 expected by end of 2018 – – On track to advance first immuno-oncology program into IND-enabling studies in fourth quarter of 2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2018-- Synlogic, Inc....
August 7, 2018
Synlogic to Webcast Presentation at the 2018 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2018-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s interim president and chief executive officer, and chief medical officer, will present a corporate update at the 2018 Wedbush PacGrow Healthcare Conference at

...
June 25, 2018
Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018

- Data highlight broad capabilities of Synlogic’s Synthetic Biotic platform to generate candidates for the potential treatment of cancer – - First program advancing into IND-enabling studies in 2H2018 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic , Inc. ( Nasdaq: SYBX ), a

...
June 25, 2018
Synlogic Joins Russell 3000® Index

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 25, 2018-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today announced the company’s addition to the Russell 3000® Index, following the Russell US Indices’ annual

...
June 11, 2018
Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria

– SYNB1618 currently being evaluated in a Phase 1/2a clinical trial in healthy volunteers and patients with Phenylketonuria (PKU); interim data expected in 2H 2018 – – Data presented in plenary session at ASM Microbe 2018 demonstrate lowering of blood phenylalanine (Phe) levels in an animal model

...
Displaying 85 - 96 of 146